
Radioligand Binding Assay Services
Radioligand Binding CRO for Receptor Pharmacology
Gifford Bioscience provides radioligand binding studies to compare compound affinity and characterize receptor binding in tissue preparations and cell-based systems.
Radioligand binding assays are considered the gold standard for measuring the affinity of ligand binding to a target receptor, due to their robustness and sensitivity.
Three Types of Radioligand Binding Assay
Competitive Radioligand Binding Assays
Used to determine the relative affinities (Ki values) of test compounds for binding to a receptor site in a membrane homogenate or cells. They are performed by incubating a range of concentrations of the unlabeled test compound with a fixed concentration of radioligand. Then, measuring the IC50 (nM) of the test compound to competitively inhibit binding of the radiolabeled ligand to its receptor. Our standard study design is for ten concentrations of the unlabeled test article over a five-log unit range, duplicate determinations.
Saturation Radioligand Binding Assays
Allow determination of the number of binding sites, Bmax (fmol/mg protein or sites per cell), in the tissue or cultured cells. Also the dissociation constant, Kd (nM), of the radioligand, to measure affinity. They are performed with increasing concentrations of the radioligand to directly measure the level of receptor binding. Our standard study design is for eight concentrations of the labeled test article over a two-log unit range, duplicate determinations.
Kinetic Radioligand Binding Assays
Used to determine the association and dissociation rates of a radiolabeled ligand from a receptor, to provide additional information for optimizing assay conditions. Our standard study design is for eight to twelve time points to obtain association or dissociation rate constants, duplicate determinations.
There are two main variations in protocol: filtration assay or scintillation proximity assay
Filtration assay protocol is to incubate the membrane homogenate or cultured cells with both the radioligand and the competing test compound (if any). Once equilibrium has been attained, receptor-bound radioligand is separated from free (unbound) radioligand using a 96-well filtration apparatus. The receptor-bound radioactivity trapped on the filters is counted and the results plotted to obtain IC50 and Ki values for the test compound, or to determine Bmax for the receptor levels. Filtration assays work well for membrane-bound receptors since membrane microsomes in the homogenate are readily trapped on the glass fiber filters.
Scintillation proximity assay protocol does not require separating bound from free radioligand. The enzyme, receptor or cultured cells are absorbed or bound onto the surface of scintillation proximity assay (SPA) beads. The receptor-coated beads are then incubated together with a radioligand and the competing test compound. SPA assays can be applied both to soluble cytoplasmic receptors and membrane-bound receptors, depending on the method used for immobilization onto the bead.
Example Data: Competitive Radioligand Binding Assay
Displacement of [3H]SR141716A binding to CB1 cannabinoid receptors in rat brain homogenate by the cannabinoid agonists AM2233 and WIN55212-2. Displacement curves are shown fitted to a two-site model with Ki values of 0.08 nM and 17 nM for AM2233 and 2 nM and 43 nM for WIN55212-2.
Example Data: Saturation Radioligand Binding Assay
Specific binding of a radioligand for the brain BZD receptor in human post-mortem brain tissue. Binding was to a single saturable site with Kd 3.2 nM and Bmax 1584 fmol/mg protein.
Specific binding of a [125I]-labeled monoclonal antibody to cell surface antigen sites on SKBR3 cells.
Example Data: Kinetic Radioligand Binding Assay
Effect of Di-n-pentyl phthalate (DNPP; 40 µM) on association rate, dissociation rate and saturation binding of the cannabinoid ligand [125I]AM251 in rat brain. The enhanced dissociation rate and lowered Bmax for [125I]AM251 binding in the presence of the inhibitor is consistent with an allosteric binding site for DNPP on the CB1 receptor.
Frequently Asked Questions about Radioligand Binding Assays
Can a radioligand binding assay be used to characterize my therapeutic and target interaction?
We have extensive experience in performing radioligand binding assays for membrane-bound targets (GPCRs, ion channels and transporters), protein aggregates (such as tau and amyloid β), and some soluble cytoplasmic receptors. We customize radioligand binding assay conditions to support the characterization of binding of a variety of therapeutic classes, including small molecules (orthosteric and allosteric modulators), peptides, and biologics. We advise on the feasibility of a radioligand binding assay for your therapeutic and target classes. We also perform SPR assays as an orthogonal technique to determine specificity, affinity and kinetics in other therapeutic and target binding interactions.
What type of radioligand binding assay do I need?
Competition assays assess your compound’s binding affinity, reported as Ki. Saturation assays measure the radioligand’s direct binding affinity (Kd) and the density of available binding sites (Bmax). Kinetic assays measure test compound association (kon) and dissociation rates (koff) and can also determine binding affinity (Kd) from the ratio of the two kinetic constants (koff/kon).
Does my compound need to be radiolabeled?
In a standard competition assay, your unlabeled test compounds are tested against a high-affinity radioligand for the target. For kinetic and saturation assays, the test compound will need to be radiolabeled.
What if there is no suitable commercial radioligand?
We can assess whether a suitable ligand can be custom radiolabeled for your study. We perform iodine-125 radiolabeling of suitable peptides, antibodies and proteins in-house and work with Novandi Chemistry AB for tritium labeling of small molecules. Binding assays work best when the radioligand has a moderate to high affinity to the target (Kd < 30 nM) and a cLogP value of < 3.5. However, the exact parameters depend on the target and expression levels.
Can you compare binding in recombinant systems and native tissue?
Yes. We perform radioligand binding in recombinant receptor preparations through to native human and animal tissue preparations. We arrange tissue sourcing and manage the ethics approval process. We can also perform radioligand binding assays in preparations from your cell lines.
Can you verify binding of the test compounds we generated by AI-driven drug discovery?
Yes, we can provide the lab validation to determine specific binding to the target of the test compounds that you have generated by AI-driven drug discovery. Test compounds can be screened in single concentration competition assays to determine the most promising lead candidates. Binding affinity (Ki) of lead candidates can be determined from competition assay concentration response curves.
Will binding show whether my compound is an agonist or antagonist?
Binding alone does not establish this, because both agonists and antagonists can bind to the same receptor. Functional assays determine how your compound affects receptor activity. We can perform functional assays to characterize agonist or antagonist activity, alongside your binding results.
What do you need to start my study?
The binding target and species, number of test compounds and the question you need answered. We will work with you to discuss a suitable radioligand, to agree study design and, if needed, discuss any known assay and test compound requirements beforehand. Depending on the study, we require 0.2 – 1 mg of each of the test compounds.
What is your turnaround time?
Typically, two to four weeks from when we have the test compounds, reagents and biological materials in hand.
What will I receive at the end of the study?
Your Final Report includes the study methods, results presented in tables and figures, the binding parameters relevant to your assay and supporting data files. Our Principal Investigator will review the data before release and is available to discuss the findings and any points affecting their interpretation.









